Meet the Principal Investigator
Rolf Brekken, Ph.D.
Dr. Brekken’s laboratory studies the tumor microenvironment. His group is particularly interested in anti-angiogenic therapy and how it affects the microenvironment of tumors. Relevant and robust modeling of pancreatic and breast cancer are also key aspects of studies in the Brekken Lab. Current studies in the laboratory focus on the function of matricellular proteins (SPARC and fibulin-5) in pancreatic cancer and the biology of anti-VEGF therapy with a focus on resistance mechanisms and hypoxia-induced tumor progression.
